| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
(E/Z)-GSK5182 primarily targets estrogen-related receptor gamma (ERRγ), acting as a highly selective inverse agonist with an IC₅₀ of 79 nM. ERRγ is an orphan nuclear receptor involved in the regulation of energy metabolism, mitochondrial biogenesis, and cellular homeostasis. By binding to ERRγ, GSK5182 modulates its transcriptional activity, thereby influencing various metabolic pathways. The compound also induces reactive oxygen species (ROS) generation in hepatocellular carcinoma cells, suggesting additional effects on cellular redox status. It does not significantly interact with other nuclear receptors at relevant concentrations, demonstrating high selectivity for ERRγ.
|
|---|---|
| ln Vitro |
In vitro, (E/Z)-GSK5182 demonstrates potent inverse agonist activity against ERRγ with an IC₅₀ of 79 nM. The compound effectively suppresses ERRγ-mediated transcriptional activity in cell-based reporter assays. In hepatocellular carcinoma cells, GSK5182 treatment leads to increased production of reactive oxygen species (ROS), which may contribute to its antiproliferative effects. The compound shows excellent selectivity for ERRγ over other nuclear receptors, making it a valuable tool for studying ERRγ-specific biological functions. Its activity can be assessed in various cell lines expressing endogenous or transfected ERRγ using luciferase reporter gene assays and ROS detection methods.
|
| ln Vivo |
Specific in vivo activity data for (E/Z)-GSK5182 are limited in the publicly available literature. As an orally active compound, GSK5182 is expected to be bioavailable and capable of modulating ERRγ activity in vivo. The compound has been investigated in animal models of metabolic diseases, including diabetes and obesity, given ERRγ's role in energy metabolism regulation. Studies have also explored its potential in cancer research, particularly in hepatocellular carcinoma models where ROS induction may contribute to antitumor efficacy. Further detailed in vivo pharmacological studies are needed to fully characterize its therapeutic potential and efficacy across different disease models.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays for (E/Z)-GSK5182 typically involve competitive binding experiments using purified ERRγ ligand-binding domain (LBD) and radiolabeled or fluorescently labeled tracer ligands. The assay measures the compound's ability to displace the tracer from the receptor, allowing calculation of IC₅₀ values. Typical assay conditions include incubation at room temperature or 4°C in buffered solutions containing appropriate salts and detergents to maintain protein stability. Binding affinity can also be assessed using surface plasmon resonance (SPR) or isothermal titration calorimetry (ITC) to determine kinetic and thermodynamic parameters. The compound's inverse agonist activity is confirmed through cell-based transcriptional repression assays.
|
| Cell Assay |
In vitro cell-based assays for (E/Z)-GSK5182 typically utilize cell lines expressing endogenous ERRγ or transfected with ERRγ expression constructs along with reporter genes containing ERRγ response elements. Cells are treated with varying concentrations of the compound for 24-48 hours, followed by luciferase reporter assays to measure transcriptional activity. ROS generation is assessed using fluorescent probes such as DCFH-DA in hepatocellular carcinoma cell lines. Cell viability and proliferation can be evaluated using MTT or CCK-8 assays. Standard cell culture conditions (37°C, 5% CO₂) with appropriate media and serum supplementation are employed. Dose-response curves are generated to determine IC₅₀ and EC₅₀ values.
|
| Animal Protocol |
In vivo animal studies with (E/Z)-GSK5182 involve oral administration of the compound to rodent models of metabolic diseases or cancer. Typical experimental designs include dosing regimens ranging from once daily to twice daily over periods of several days to weeks. Endpoints may include measurements of metabolic parameters such as blood glucose, insulin levels, and lipid profiles in diabetes and obesity models. In cancer models, tumor growth inhibition, ROS levels in tumor tissues, and survival outcomes are commonly assessed. Pharmacokinetic sampling is often integrated to establish exposure-response relationships. All procedures must comply with institutional animal care and use guidelines.
|
| ADME/Pharmacokinetics |
Specific pharmacokinetic data for (E/Z)-GSK5182 are not extensively detailed in the public domain. The compound is described as orally active, indicating reasonable oral bioavailability. It has a calculated LogP of 5.9, suggesting moderate lipophilicity that may influence its absorption and distribution characteristics. The compound is soluble in DMSO at ≥75 mg/mL (179.62 mM). For in vivo administration, formulations such as 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% saline can be used. The compound is stable when stored as a powder at -20°C for up to 3 years or at 4°C for up to 2 years.
|
| Toxicity/Toxicokinetics |
Toxicological data for (E/Z)-GSK5182 are not extensively documented in the publicly available literature. The compound is intended for research use only and is not approved for human or veterinary therapeutic applications. Standard safety precautions should be observed when handling this compound, including the use of appropriate personal protective equipment such as gloves, lab coats, and eye protection. As with all research chemicals, comprehensive toxicological profiling including acute toxicity, genotoxicity, and organ-specific toxicity studies would be required before any consideration for clinical development. The compound should be handled in well-ventilated areas with proper waste disposal procedures.
|
| References |
|
| Additional Infomation |
(E/Z)-GSK5182 (CAS#: 2699724-40-6) has a molecular formula of C₂₇H₃₁NO₃ and a molecular weight of 417.54 g/mol. Its IUPAC name is (Z)-4-(1-(4-(2-(dimethylamino)ethoxy)phenyl)-5-hydroxy-2-phenylpent-1-en-1-yl)phenol. The compound is a racemic mixture of (E)- and (Z)-isomers. It is typically stored as a powder at -20°C (stable for 3 years) or 4°C (stable for 2 years); in solvent, it can be stored at -80°C for 6 months or -20°C for 1 month. The compound is soluble in DMSO at ≥75 mg/mL. GSK5182 is not a drug and has not undergone clinical trials or received regulatory approval for therapeutic use; it is strictly a research reagent for studying ERRγ biology and metabolic diseases.
|
| Molecular Formula |
C27H31NO3
|
|---|---|
| Molecular Weight |
417.539947748184
|
| Exact Mass |
417.23
|
| CAS # |
2699724-40-6
|
| Related CAS # |
GSK5182;877387-37-6
|
| PubChem CID |
6852176
|
| Appearance |
Off-white to light yellow solid powder
|
| LogP |
5.9
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
10
|
| Heavy Atom Count |
31
|
| Complexity |
525
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CN(C)CCOC1=CC=C(C=C1)/C(=C(/CCCO)\C2=CC=CC=C2)/C3=CC=C(C=C3)O
|
| InChi Key |
ZVSFNBNLNLXEFQ-RQZHXJHFSA-N
|
| InChi Code |
InChI=1S/C27H31NO3/c1-28(2)18-20-31-25-16-12-23(13-17-25)27(22-10-14-24(30)15-11-22)26(9-6-19-29)21-7-4-3-5-8-21/h3-5,7-8,10-17,29-30H,6,9,18-20H2,1-2H3/b27-26-
|
| Chemical Name |
4-[(Z)-1-[4-[2-(dimethylamino)ethoxy]phenyl]-5-hydroxy-2-phenylpent-1-enyl]phenol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ≥ 75 mg/mL (179.62 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 3.75 mg/mL (8.98 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 37.5 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 3.75 mg/mL (8.98 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 37.5 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 3.75 mg/mL (8.98 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3950 mL | 11.9749 mL | 23.9498 mL | |
| 5 mM | 0.4790 mL | 2.3950 mL | 4.7900 mL | |
| 10 mM | 0.2395 mL | 1.1975 mL | 2.3950 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
